Terms: = Prostate cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Diagnosis
173 results:
1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
2. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi P; Freeman D; Thomas J; Ravi A; Mantia C; McGregor BA; Berchuck JE; Epstein I; Budde P; Ahangarian Abhari B; Rupieper E; Gajewski J; Schubert AS; Kilian AL; Bräutigam M; Zucht HD; Sonpavde G
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309723
[TBL] [Abstract] [Full Text] [Related]
5. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
6. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract] [Full Text] [Related]
7. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
8. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive prostate cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract] [Full Text] [Related]
9. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant prostate cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract] [Full Text] [Related]
10. Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with prostate cancer.
Iyer HS; Kensler KH; Vaselkiv JB; Stopsack KH; Roscoe C; Bandera EV; Qin B; Jang TL; Lotan TL; James P; Hart JE; Mucci LA; Laden F; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1120-1123. PubMed ID: 37249585
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive prostate cancer.
Sutera P; Song Y; Van der Eecken K; Shetty AC; English K; Hodges T; Chang J; Fonteyne V; Rana Z; Ren L; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Song DY; Pienta K; Feng FY; Joniau S; Lotan T; Lane B; Kiess A; Rowe S; Pomper M; DeWeese T; Deek M; Sweeney C; Ost P; Tran PT
Eur Urol; 2023 Dec; 84(6):531-535. PubMed ID: 37173210
[TBL] [Abstract] [Full Text] [Related]
12. IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms.
Mei W; Dong Y; Gu Y; Kapoor A; Lin X; Su Y; Vega Neira S; Tang D
J Adv Res; 2023 Dec; 54():195-210. PubMed ID: 36681115
[TBL] [Abstract] [Full Text] [Related]
13. Prior Thyroid and Nonthyroid cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid cancer.
Chen YH; Cabanillas M; Sperling J; Xu L; Goswami M; Maniakas A; Williams MD; Lai SY; Busaidy N; Dadu R; Zafereo ME; Wang JR
Thyroid; 2023 Mar; 33(3):321-329. PubMed ID: 36511380
[No Abstract] [Full Text] [Related]
14. Recent Progress in Biosensors for Detection of Tumor Biomarkers.
Li M; Jiang F; Xue L; Peng C; Shi Z; Zhang Z; Li J; Pan Y; Wang X; Feng C; Qiao D; Chen Z; Luo Q; Chen X
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364157
[TBL] [Abstract] [Full Text] [Related]
15. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract] [Full Text] [Related]
16. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Rautajoki KJ; Jaatinen S; Tiihonen AM; Annala M; Vuorinen EM; Kivinen A; Rauhala MJ; Maass KK; Pajtler KW; Yli-Harja O; Helén P; Haapasalo J; Haapasalo H; Zhang W; Nykter M
Sci Rep; 2022 Aug; 12(1):14083. PubMed ID: 35982066
[TBL] [Abstract] [Full Text] [Related]
17. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
19. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
20. Genomic Features of Lung-Recurrent Hormone-Sensitive prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
[Next]
